We identified impaired lysosomal degradation of heparan sulfate proteoglycans as a potential contributor to disease pathogenesis, providing a mechanistic explanation for the previously observed association between lysosomal storage disorders and pancreatic cancer. The gene discussed is CD44; the disease is lysosomal storage disease.